Ardent Health (ARDT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 5.2% year-over-year to $1.45 billion, driven by 6.4% admissions growth, improved case mix, and strategic execution.

• Adjusted EBITDA rose 15.3% to $98 million, with margin expanding 50 basis points to 6.7%.

• Net income attributable to Ardent Health was $26.3 million ($0.19 per share), up from $20.8 million ($0.17 per share) in Q3 2023.

• Completed IPO in July 2024, raising $208.7 million in net proceeds and supporting balance sheet strength.

• Strategic initiatives in service line optimization, outpatient expansion, and technology, including AI deployment, supported growth and efficiency.

Financial highlights

• Q3 2024 total revenue: $1.45 billion (+5.2% YoY); adjusted EBITDA: $98 million (+15.3% YoY); margin: 6.7%.

• Adjusted admissions grew 3.8% year-over-year; admissions up 6.4%; total surgeries up 0.3%.

• Net patient service revenue per adjusted admission increased 0.9% year-over-year; growth over 3% excluding non-recurring items.

• Cash and cash equivalents at September 30, 2024: $563 million; available liquidity: $851 million.

• Operating cash flow was $90 million in Q3 2024, up slightly from $89 million in Q3 2023.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $5.8–$5.90 billion; adjusted EBITDA guidance increased to $425–$440 million.

• Net income guidance lowered to $156–$176 million due to delayed insurance proceeds from a cybersecurity incident, with collection expected in 2025.

• Adjusted admissions growth forecast at 4.5–5.0%; net patient service revenue per adjusted admission growth at 2.6–3.3%.

• Capital expenditures projected at $170–$185 million for 2024.

• Multi-year journey to mid-teens Adjusted EBITDA margins remains on track, supported by Medicaid DPP programs and operational initiatives.